Ligand validation:5DYY

NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose

NAG is a Ligand Of Interest in 5DYY designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
5DYY_NAG_B_614	37%	80%	0.198	0.895	0.3	0.54	-	-	0	0	100%	0.9333
5DYY_NAG_A_614	29%	42%	0.201	0.86	0.9	1.32	1	1	0	1	100%	0.9333
5DYY_NAG_B_616	12%	58%	0.235	0.764	0.6	1	1	1	0	1	100%	0.9333
5DYY_NAG_B_613	11%	71%	0.235	0.756	0.36	0.75	-	1	0	0	100%	0.9333
5DYY_NAG_A_607	8%	60%	0.346	0.818	0.76	0.76	-	-	0	0	100%	0.9333
5DYY_NAG_B_609	7%	57%	0.341	0.792	0.37	1.24	-	3	0	1	100%	0.9333
5DYY_NAG_B_608	4%	61%	0.287	0.662	0.68	0.8	1	-	0	1	100%	0.9333
5DYY_NAG_B_615	3%	69%	0.336	0.658	0.56	0.65	-	1	0	0	100%	0.9333
5DYY_NAG_B_607	2%	28%	0.38	0.67	1.27	1.6	2	3	0	1	100%	0.9333
5LKR_NAG_B_608	57%	68%	0.094	0.869	0.56	0.67	-	1	0	0	100%	0.9333
5DYW_NAG_A_625	55%	54%	0.134	0.9	0.64	1.11	1	1	0	1	100%	0.9333
6F7Q_NAG_B_611	51%	56%	0.137	0.89	0.82	0.89	1	1	0	0	100%	0.896
7Q1P_NAG_A_603	49%	45%	0.122	0.867	1.1	1.03	1	1	0	0	100%	0.9333
1P0I_NAG_A_538	48%	58%	0.135	0.877	0.77	0.83	-	-	0	0	100%	0.6667
5LDS_NAG_B_1007	100%	67%	0.022	0.995	0.48	0.79	-	-	0	0	100%	0.9333
5O5D_NAG_A_601	100%	65%	0.022	0.994	0.32	0.99	-	1	0	0	100%	0.9333
6MUG_NAG_G_629	100%	76%	0.022	0.994	0.35	0.58	-	-	0	0	100%	0.9333
3PPS_NAG_B_760	100%	44%	0.028	0.993	0.57	1.57	-	3	0	0	100%	0.9333
5O59_NAG_A_601	100%	70%	0.024	0.993	0.3	0.85	-	-	0	0	100%	0.9333

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.